Interchange of vaccine products; Rebound 4 days after completing treatment, worse symptoms than originally reported/Covid-19; This spontaneous case was reported by an other health care professional and describes the occurrence of SUSPECTED COVID-19 (Rebound 4 days after completing treatment, worse symptoms than originally reported/Covid-19) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for COVID-19 prophylaxis.    Medical condition included that patient was not pregnant at the time of report.  Previously administered products included for Product used for unknown indication: Janssen. Past adverse reactions to the above products included No adverse event with Janssen.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form and second dose of COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) (unknown route) 1 dosage form. In June 2022, the patient experienced SUSPECTED COVID-19 (Rebound 4 days after completing treatment, worse symptoms than originally reported/Covid-19). On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). The patient was treated with PREDNISONE at an unspecified dose and frequency. At the time of the report, SUSPECTED COVID-19 (Rebound 4 days after completing treatment, worse symptoms than originally reported/Covid-19) had not resolved and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant products were not reported.  It was reported that patient took unspecified drug from 22-Jun-2022 till 27-Jun-2022 for the treatment of COVID-19. On 01-Jul-2022 the patient experienced rebound 4 days after completing treatment with an unspecified drug. The action taken with unspecified drug was drug discontinued. Causality for Janssen was reported as possible for reporter and company causality.  The treatment medication also included short acting Beta Agonist(SABAs).  Company Comment: This spontaneous case of Interchange of vaccine products, concerns a 41-year-old female patient, with previous vaccination of JANSSEN COVID-19 VACCINE, who experienced the unexpected non-serious AESI of Suspected COVID-19. The event occurred on an unknown date interval after receiving the third dose of mRNA-1273 Vaccine. Treatment included Prednisone at an unspecified dose and frequency and short acting Beta Agonist (SABAs). The outcome of the event was reported as not resolved. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.   Reporter did not allow further contact; Sender's Comments: This spontaneous case of Interchange of vaccine products, concerns a 41-year-old female patient, with previous vaccination of JANSSEN COVID-19 VACCINE, who experienced the unexpected non-serious AESI of Suspected COVID-19. The event occurred on an unknown date interval after receiving the third dose of mRNA-1273 Vaccine. Treatment included Prednisone at an unspecified dose and frequency and short acting Beta Agonist (SABAs). The outcome of the event was reported as not resolved. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.